Clay Siegall, Ph.D., is the Founder, Chief Executive Officer, and Chairman of the Board for Seattle Genetics. Dr. Siegall maintains a blog that is filled with stories and articles that he finds of interest. One article he posted is part science and part funny as it describes how the UK research submersible Boaty McBoatface went out on its first Antartic mission. The name Boaty McBoatface had won a public poll to name the research vessel it’s stored on but that name was overruled by the Natural Environment Research Council. As a concession to the public they did name this research vehicle the funny name.
Another article that Dr. Clay Siegall posted was about a theory that Humans and Neanderthal’s kissed each other, or at least shared food. Researchers looking at plaque buildup on the teeth of Neanderthals discovered a microbial genome that goes along with gum disease. The presence of this microbial genome likely means that Humans and Neanderthal’s got along quite a bit better than has been thought.
Dr. Siegall has dedicated his career to finding cures for cancer. His company is the industry leader in developing antibody-drug conjugates to treat different forms of cancer. So far Seattle Genetics has one drug on the market, Adcetris, which treats two different forms of Lymphoma. Adcetris is now approved for use in over 50 countries around the world. They currently also have 9 other cancer drugs that are at different levels of development.
Dr. Siegall started his professional career in healthcare in 1988 at the National Cancer Institute, National Institutes of Health. In 1991 he performed r&d at the Bristol-Meyers Squibb Pharmaceutical Research Institute. It was in 1998 that he co-founded Seattle Genetics in Bothell, Washington, which is a suburb of Seattle.
As the leader of Seattle Genetics, Dr. Clay Siegall manages the many collaboration agreements that Seattle Genetics has in place. He has partnered with Takeda Oncology Company to develop and commercialize Adcetris. He has also shared Seattle Genetics anti-body conjugate technology with other pharmaceutical and biotechnology firms including AbbVie, GlaxoSmithKline, Pfizer, Inc., Celidex Therapeutics, Inc., and Daichi Sankyo.